CHMP adopts positive opinion for treatment of acute angioedema attacks in children with hereditary angioedema with RUCONEST®

''As we continue to see increasing demand for RUCONEST® in the treatment of HAE, we are pleased to announce this step forward in this paediatric label expansion. This will enable us to treat attacks of patients of all ages living with HAE in the EU'' — Sijmen de Vries - CEO Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗